NVO Jun 2024 143.000 call
| Previous close | 4.3000 |
| Open | 2.8000 |
| Bid | 1.8200 |
| Ask | 1.9000 |
| Strike | 143.00 |
| Expiry date | 2024-06-28 |
| Day's range | 1.2900 - 2.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 286 |
- Yahoo Finance Video
The S&P 500 and Nvidia, Chipotle stock split: Morning Brief
It's the middle of the week, but stocks aren't slowing down. The Morning Brief keeps investors informed on the latest market (^DJI, ^IXIC, ^GSPC) movements and top industry stories to start the trading day off right, hosted by Seana Smith and Brad Smith. In today's episode, Stifel Chief Equity Strategist Barry Bannister weighs in on Nvidia's (NVDA) broader market influence on tech-heavy indices like the S&P 500. CFRA Research Energy Equity Analyst and Deputy Research Director Stewart Glickman also comes on to discuss FedEx (FDX) fourth-quarter earnings. Other top trending stocks in Yahoo Finance's purview for this morning include Chipotle Mexican Grill (CMG) after its 50-for-1 stock split takes effect and begins trading at an adjusted price; Rivian (RIVN) after Volkswagen (VOW3.DE, VWAGY) announces its willingness to invest up to $5 billion in a joint EV software venture; and Southwest Airlines (LUV) as it slashes its full-year revenue guidance. This post was written by Luke Carberry Mogan.
- Yahoo Finance Video
Novo Nordisk stock rises on Wegovy approval in China
Shares of Novo Nordisk (NVO) are soaring to an all-time high after its popular GLP-1 weight-loss drug, Wegovy, was approved in China. Yahoo Finance's Anjalee Khemlani reports more on the story and the weight-loss drug market in China. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
GlobeNewswireNovo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7 billion related to the intangible asset ocedurenone in the second quarter of 2024. Novo Nordisk acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023. The phase 3 lead indication trial CLARION-CKD, which investigated ocedurenone in patients with uncontrolled hypertension and advanced chronic ki
